These findings emphasize the need for targeted, system-level strategies to improve access, adherence, and coordinated care for individuals with schizophrenia within Medicaid programs.
These findings emphasize the need for targeted, system-level strategies to improve access, adherence, and coordinated care for individuals with schizophrenia within Medicaid programs.
No summary available
No summary available
No summary available
This session reviews practical, evidence-based approaches for bringing overdose prevention and opioid use disorder (OUD) treatment into pediatric primary care. It will cover screening and risk assessment, brief counseling to reduce the consequences of drug use, naloxone distribution, and pathways for initiating and managing medications for OUD (including buprenorphine).
This webinar will detail the benefits of SBIRT, the appropriate screening tools to use and how to use these to facilitate change-focused conversations.
The FDA granted de novo approval for a neuromodulation device to treat symptoms associated with post-traumatic stress disorder (PTSD). The wearable, non-invasive device -- dubbed Modius Spero -- uses electrical vestibular system stimulation to target specific brain areas. It is prescribed and overseen by a healthcare professional as part of a comprehensive PTSD care plan.
The Department of Veterans Affairs (VA) on Tuesday announced a new clinical trial of methylenedioxymethamphetamine-assisted therapy, more commonly known as MDMA, to evaluate the safety and efficacy when treating current and former military personnel for severe mental health disorders including posttraumatic stress disorder (PTSD) and alcohol use disorder.
The SSP-based model provided rapid access to buprenorphine prescriptions, but precipitated withdrawal was a common complication.
Public sentiment on Regulations.gov supports the United States Drug Enforcement Administration's proposal for cannabis rescheduling, though the majority views the proposed Schedule III classification as inadequate and supports further rescheduling or complete de-scheduling of cannabis.
This study offers novel data on opioid-related medication access for adolescents with illicit fentanyl exposure.
Formalizing FA assessment and diagnosis, and improving reimbursement mechanisms, may reduce potential health inequities between market-driven and publicly funded SUD treatment centers in FA treatment and referral resources.
This study's findings suggest that provision of in-jail MOUD could improve methadone uptake in the community.
Social anxiety and psychiatric concerns are salient barriers to attending a variety of MHG groups and to MHG involvement.
This randomized controlled trial provides the first evidence that a pharmacological intervention, buprenorphine, significantly sustains and enhances the antisuicidal effects of ketamine in MDD.
This review aimed to update current knowledge on causality and risk relationships to inform global and national comparative risk assessments for alcohol.
No summary available
No summary available
No summary available
No summary available
The AAPP Foundation Board of Directors is proud of the Foundation's work in 2025! See our impact in the 2025 Annual Report.
No summary available
Expand availability to clozapine for those living with schizophrenia. Register now for the CURESZ Foundation Clozapine Panel!
The CURESZ Foundation (Comprehensive Understanding via Research and Education into SchiZophrenia) founded by Bethany Yeiser and Dr. Henry Nasarallah has assembled a Clozapine in Schizophrenia Expert Panel (CLOSZE). The goal is to assist individuals living with schizophrenia and/or caregivers in finding a clinician who can assist them in trying clozapine. AAPP encourages psychiatric pharmacists to sign up for the registry so that patients/caregivers can outreach to establish ongoing care.
No summary available